Harvett, Some of us who are original holders are here because of...

Harvett,

Some of us who are original holders are here because of the drug, and in spite of, not because of, the management. My personal concern is not a lack of puffery - I don't believe it serves a company well in the long run - but a lack of any urgency and innovation in getting results. Compare KZA with the number of trials and the pace with which NOX has proceeded and you can understand why KZA is the poor relation, despite having the more modern technology.

I know you don't like the man, but you should consider having a look at the latest NOX blog post as a model both for how to communicate to shareholders, and how to spread risk and identify trial options through the use of multiple Phase 1 trials - in stark contrast to KZA.